https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-12-13 / Cancer Immunol. Immunother. 2009 Dec;58(12):1935-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-12-13 / Cancer Immunol. Immunother. 2009 Dec;58(12):1935-92008-12-13 00:00:002008-12-13 00:00:00Mechanisms of murine dendritic cell antitumor dysfunction in aging
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-12-06 / Gynecol. Oncol. 2009 Feb;112(2):384-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-12-06 / Gynecol. Oncol. 2009 Feb;112(2):384-82008-12-06 00:00:002008-12-06 00:00:00Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer – a phase II study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-12-04 / Lung Cancer 2009 Jul;65(1):1-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-12-04 / Lung Cancer 2009 Jul;65(1):1-82008-12-04 00:00:002019-02-15 08:34:57Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-12-01 / Int J Hyperthermia 2008 Dec;24(8):649-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-12-01 / Int J Hyperthermia 2008 Dec;24(8):649-622008-12-01 00:00:002019-02-15 09:17:39Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-28 / Cancer Lett. 2008 Nov;271(2):333-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-28 / Cancer Lett. 2008 Nov;271(2):333-412008-11-28 00:00:002019-02-15 09:16:51Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-27 / Pigment Cell Melanoma Res 2009 Feb;22(1):30-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-27 / Pigment Cell Melanoma Res 2009 Feb;22(1):30-412008-11-27 00:00:002019-02-15 09:19:13Dendritic cells in the skin–potential use for melanoma treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-26 / Clin. Vaccine Immunol. 2009 Feb;16(2):233-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-26 / Clin. Vaccine Immunol. 2009 Feb;16(2):233-402008-11-26 00:00:002019-02-15 09:15:03Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-16 / Jpn. J. Clin. Oncol. 2009 Feb;39(2):73-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-16 / Jpn. J. Clin. Oncol. 2009 Feb;39(2):73-802008-11-16 00:00:002019-02-15 08:44:32Recent advances in cancer vaccines: an overview
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-15 / Clin. Cancer Res. 2008 Nov;14(22):7358-66
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-15 / Clin. Cancer Res. 2008 Nov;14(22):7358-662008-11-15 00:00:002019-02-15 09:19:17Tumor infection by oncolytic reovirus primes adaptive antitumor immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-15 / Cancer Res. 2008 Nov;68(22):9441-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-15 / Cancer Res. 2008 Nov;68(22):9441-502008-11-15 00:00:002019-02-15 09:19:16Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells
